Refine by
Transdermal Articles & Analysis
31 news found
CD Formulation, a leading force in biotechnology research and development, is at the forefront of revolutionizing transdermal delivery systems. As the demand for non-invasive, efficient drug delivery systems grows, CD Formulation has announced its abilities in providing a few transdermal delivery enhancement technologies. Transdermal Delivery: ...
With Protheragen-ING’s microneedle technology, controlled drug delivery can be achieved using precise and efficient use of both hollow and solid structures made from any materials (silicons, metals or biodegradable polymers). The use of microneedles in transdermal drug delivery is much better than other methods, such as hypodermic needles and topical creams. ...
The offer incorporates a wide range of services, including transdermal patch development, a major service where CD Formulation shines by providing custom membrane permeation-controlled systems and matrix diffusion-controlled systems to achieve optimal drug delivery. ...
The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles made of hydrogel, which can deliver drugs directly into the skin. ...
As further research and development take place in this rapidly expanding field, the potential applications and benefits of varieties of novel drug delivery systems such as transdermal patches drug delivery system are expected to grow, heralding a new era in pharmaceutical innovation. ...
These innovative systems have revolutionized the way medications are administered, enhancing patient comfort and ensuring optimal therapeutic efficacy. Transdermal drug delivery systems are very popular due to their benefits, such as improving bioavailability and reducing side effects. ...
With a relentless commitment to delivering innovative solutions and excellent customer service, CD Formulation has built a strong reputation in the industry, particularly in fields like Transdermal Patches Drug Delivery System, Oral Thin Films Drug Delivery, Microneedle Technology, Microsphere Development, etc. ...
Through its expertise in various cutting-edge technologies such as microneedle and thin film technologies, transdermal patches, microencapsulation, and nanoparticle development, CD Formulation is revolutionizing the way drugs are delivered to patients, ultimately improving pharmacokinetics and pharmacodynamics. ...
In addition to CAR-T/CAR-NK cells development, CD Formulation also provides other novel drug delivery system services, including: Microneedle Technology, Oral Thin Films Drug Delivery, Transdermal Patches Drug Delivery System, Microencapsulation Drug Delivery System, Nanoparticle Development, Microparticle Depots Design and Development, Emulsion Formulation, Coupled Targeted ...
“Our new collection of pharmaceutical excipients covers a wide range of dosage forms, including liquids, solids, semi-solids, controlled-release, transdermal, mucosal, and micro drug delivery systems. Each formulation is meticulously designed to meet the unique needs of different medications and patient populations,” said the Marketing Director of CD Formulation. ...
Microneedles, on the other hand, are tiny needles that can penetrate the skin surface for transdermal delivery of drugs. “Our innovative drug delivery solutions are ideal for a wide range of pharmaceutical and biotech applications, such as gene therapy, immunotherapy, hormonal therapy, anti-infectives, and vaccines,” said the Marketing Chief of CD Formulation. ...
(CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). ...
As for now, CD Formulation is capable of conducting the following services upon customers' requests: l Microneedle Technology Services l Oral Thin Films Technology Services l Transdermal Patches Drug Delivery System Services l Microencapsulation Technology Services l Nanoparticle Development Services for Drug Delivery System l Microparticle Depots Design and Development Services ...
STAR-LLD program: three delivery systems Starton is pursuing three delivery systems for STAR-LLD, in addition to the subcutaneous ambulatory infusion under investigation in the ongoing Phase 1 clinical trial, the Company also has progressed with its transdermal adhesive patch development and development of a patch/pump on-body injector (OBI). ...
Oral Podium Presentation Details Title: Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017) Date: Tuesday, May 31, 2022 Time: 4:20 p.m. ...
” STAR-LLD program: three delivery systems Starton is pursuing three delivery systems for STAR-LLD, in addition to the subcutaneous ambulatory infusion under investigation in the ongoing Phase 1 clinical trial, the Company also has progressed with its transdermal adhesive patch development and development of a patch/pump on-body injector (OBI). ...
(Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present virtually at the H.C. ...
(Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2022, and provided an overview of recent operational highlights and a pipeline update. ...
(Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being held both in-person and virtually May 11-14, 2022, from Austin, TX. ...
(Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being held both in-person and virtually May 11-14, 2022, from Austin, TX. ...